Perrigo Company plc Deferred Federal Income Tax Expense (Benefit)
Perrigo Company plc (PRGO) reported Deferred Federal Income Tax Expense (Benefit) of -$3.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-26
- Perrigo Company plc deferred federal income tax expense (benefit) for fiscal 2025 was -$3.30M.
- Perrigo Company plc deferred federal income tax expense (benefit) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Perrigo Company plc deferred federal income tax expense (benefit) for fiscal 2023 was $200.00K, a 71.43% decline from fiscal 2022.
- Perrigo Company plc deferred federal income tax expense (benefit) for fiscal 2022 was $700.00K, a 75.00% increase from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 6 month | Deferred Federal Income Tax Expense (Benefit) 6 month as first filed | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | -$3.30M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $200.00K 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $700.00K 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $400.00K 10-K · filed 2024-02-27 | |||
| 2020-12-31 | -$100.00K 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2018-12-31 | -$13.90M 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $13.10M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | -$549.40M 10-K · filed 2019-02-27 | -$7.60M 10-K · filed 2017-05-22 | ||
| 2015-12-31 | -$23.10M 10-K · filed 2018-03-01 | -$32.50M 10-KT · filed 2016-02-25 | ||
| 2015-06-27 | $11.10M 10-K · filed 2018-03-01 | -$17.50M 10-K · filed 2015-08-13 | ||
| 2014-06-28 | $8.40M 10-K · filed 2017-05-22 | $7.80M 10-K · filed 2014-08-14 | ||
| 2013-06-29 | $16.60M 10-KT · filed 2016-02-25 | |||
| 2012-06-30 | $32.60M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |